Mnemo: advancing next-generation cell therapies against epigenetic antigens

Mnemo has raised the largest ever series A round for a French biotech to develop a next-generation CAR T platform and bring its cell therapies into a new target space against epigenetic antigens.

Founding investor Sofinnova Partners, Casdin Capital and an undisclosed investor co-led Paris-based Mnemo Therapeutics’ €75 million ($90.9 million) A round. Alexandria Venture Investments, Emerson Collective and Redmile Group also participated...